Sremac, M., Paić, F., Ravić, K., Šerman, Lj., Pavičić Dujmović, A., Brčić, I. ... Martić, T. (2021). Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma. Oncology Letters, 22. (6). doi: 10.3892/ol.2021.13083
Sremac, Maja, et al. "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma." Oncology Letters, vol. 22, br. 6, 2021. https://doi.org/10.3892/ol.2021.13083
Sremac, Maja, Frane Paić, Katja Ravić, Ljiljana Šerman, Aja Pavičić Dujmović, Iva Brčić, Željko Krznarić i Tamara Martić. "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma." Oncology Letters 22, br. 6 (2021). https://doi.org/10.3892/ol.2021.13083
Sremac, M., et al. (2021) 'Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma', Oncology Letters, 22(6). doi: 10.3892/ol.2021.13083
Sremac M, Paić F, Ravić K, Šerman Lj, Pavičić Dujmović A, Brčić I, i sur.. Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma. Oncology Letters [Internet]. 08.10.2021. [pristupljeno 08.11.2024.];22(6). doi: 10.3892/ol.2021.13083
M. Sremac, et al., "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma", Oncology Letters, vol. 22, br. 6, Listopad 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:791452. [Citirano: 08.11.2024.]